SIC
INMB icon

SJS Investment Consulting’s INmune Bio INMB Stock Holding History

SJS Investment Consulting’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67 Buy
41
+32
+356% +$44 ﹤0.01% 2681
2026
Q1 		$11 Buy
+9
New +$13 ﹤0.01% 2420

Other funds holding INMB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

SJS Investment Consulting's INMB Position: Q2 2026 in Review

SJS Investment Consulting increased its INmune Bio (INMB) stake by 356% in Q2 2026, buying an estimated $44 and bringing the position to 41 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #2681.

SJS Investment Consulting first reported a position in INMB in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • SJS Investment Consulting held 41 shares of INmune Bio worth $67 as of Q2 2026.
  • SJS Investment Consulting bought 32 INmune Bio shares in Q2 2026, an estimated $44.
  • INmune Bio made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2681 holding.
  • SJS Investment Consulting first reported a position in INmune Bio in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.